The Wall Street Journal (online registration rquired): LONDON—The U.S. Department of Justice is closing a probe into AstraZeneca PLC's heart drug Brilinta, removing a significant cloud over the U.K. drug maker's outlook, the company said Tuesday.
Brilinta was approved in the U.S. in 2011, but the Justice Department cast doubts over the future of the drug last October when it decided to investigate a clinical trial that demonstrated Brilinta's benefits over a rival treatment
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now